<DOC>
	<DOCNO>NCT01098903</DOCNO>
	<brief_summary>Sunitinib anticancer drug , like drug , effect varies person person . This partly due variation well person eradicate drug body . This lead toxicity drug eliminate slowly . Just important inadvertent underdosing people eliminate drug quickly may lead reduce anti-cancer effect . The investigator group develop battery test may measure individual clear drug body . The investigator intend apply test group patient take sunitinib see whether test help predict level sunitinib body also side effect . If test seem promise study may possible simple test patient receive sunitinib best dose chosen . The test involve identify gene involve drug elimination ( CYP3A , ABCB1 , ABCG2 , OCT1 , OATP ) well directly measure elimination use marker drug ( midazolam clearance sestamibi liver clearance ) .</brief_summary>
	<brief_title>Predictive Value Drug Elimination Gene Polymorphisms Clearance Dose Adjustment Sunitinib Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Age &gt; 18 A malignancy treat single agent sunitinib ECOG 0 , 1 2 time study accruement Any stable dose therapy sunitinib ( define dose change within 3 week prior blood collection pharmacokinetics ) Adequate liver renal function define serum bilirubin concentration le 2 x ULN , AST ALT le 2.5 x ULN , serum creatinine concentration le 2 x ULN No known primary liver disease severe uncontrolled concurrent medical condition within first 3 month treatment sunitinib . Patients participate clinical study sunitinib suitable study . Signed informed consent Patients must Class Â¾ cardiac problem define New York Heart Association criterion severe uncontrolled concurrent medical disease . Patients must pregnant nursing must use effective contraception method Patients unable sign inform consent Patients unable give blood Patients know midazolam allergy include Patients must pregnant nursing must use effective contraception method Patients bonemarrowtransplantation prior sunitinib treatment Patients must take routine systemic corticoid therapy Patients must take therapeutic warfarin warfarin derivates dos anticoagulation time study test least 2 week warfarin free period time prior . Patients require anticoagulation may use lowmolecular weight heparin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>sunitinib</keyword>
	<keyword>cancer</keyword>
	<keyword>pharmacogenomics</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Patients malignancy go treat sunitinib</keyword>
	<keyword>doseindividualism</keyword>
</DOC>